Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience

Int J Pediatr Otorhinolaryngol. 2010 Nov;74(11):1254-7. doi: 10.1016/j.ijporl.2010.07.025. Epub 2010 Aug 30.

Abstract

Objective: Preliminary assessment of the efficacy of propranolol on subglottic hemangioma in children on a nation-wide scale.

Methods: Multicentric, retrospective study of clinical files of 14 children; pre- and post-treatment endoscopies.

Results: Mean age at diagnosis was 2.3 (0.7-4) months. Mean percentage of airway obstruction was 68% (15-90) before propranolol introduction. Propranolol was started at 5.2 (0.7-16) months of age. This treatment was effective in all cases with a mean regression of the stenosis to 22% after 2 weeks and 12% after 4 weeks. Other medical treatments (steroids) could be stopped. In one patient, a side effect of propranolol motivated the switch to another β-blocker. In four patients, treatment was stopped after 5.2 (1-10) months with a relapse in 2 (50%) cases. One of these two patients developed a resistance to propranolol and required a surgical procedure by external approach.

Conclusion: This preliminary nation-wide survey confirms propranolol high effectiveness against airways' localization of infantile hemangiomas. Propranolol also allows alleviation or cut-off of previous medical treatments. However, recurrences are possible after early treatment interruption.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Airway Obstruction / drug therapy
  • Airway Obstruction / etiology
  • Drug Resistance
  • Hemangioma / congenital
  • Hemangioma / drug therapy*
  • Humans
  • Infant
  • Infant, Newborn
  • Laryngeal Neoplasms / congenital
  • Laryngeal Neoplasms / drug therapy*
  • Propranolol / therapeutic use*
  • Recurrence
  • Retrospective Studies
  • Tracheal Neoplasms / congenital
  • Tracheal Neoplasms / drug therapy*

Substances

  • Adrenergic beta-Antagonists
  • Propranolol